RESUMO
Previous perfluorocarbon (PFC) emulsions have been associated with transient adverse events (i.e., platelet activation, decreased platelet count, febrile responses, changes in hemodynamic function). The Phase I studies described in this report were parallel, randomized, double-blinded, placebo-controlled studies conducted in 48 healthy volunteers (n = 24 per study) with perflubron emulsion (Oxygent; Alliance Pharmaceutical Corp., San Diego, CA). Because of the decreased platelet counts observed with previous PFC emulsions and the intended use of perflubron emulsion in surgical patients, these studies assessed postdosing coagulation responses and hemostasis. PFC pharmacokinetic variables were also evaluated. The primary endpoint for examination of coagulation effects was prospectively defined as bleeding time. Subjects received either saline (3 mL/kg) control, or perflubron emulsion at 1.2 g PFC/kg or 1.8 g PFC/kg, and were evaluated for a 14-day period. No postinfusion changes in bleeding time or differences in ex vivo agonist-induced platelet aggregation were observed. A 17% reduction in platelet count was observed 3 days after dosing in the 1.8-g PFC/kg group; levels recovered to baseline by Day 7. The intravascular half-life of perflubron for the first 24 h was dose dependent: 9.4+/-2.2 h and 6.1+/-1.9 h in the 1.8- and 1.2-g PFC/kg groups, respectively. Results indicate that this perflubron emulsion did not affect coagulation function in healthy volunteers.
Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Meios de Contraste/farmacologia , Fluorocarbonos/farmacologia , Adolescente , Adulto , Meios de Contraste/efeitos adversos , Meios de Contraste/farmacocinética , Relação Dose-Resposta a Droga , Método Duplo-Cego , Emulsões , Feminino , Febre/induzido quimicamente , Fluorocarbonos/efeitos adversos , Fluorocarbonos/farmacocinética , Seguimentos , Meia-Vida , Hemostasia/efeitos dos fármacos , Humanos , Hidrocarbonetos Bromados , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Placebos , Ativação Plaquetária/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacos , Contagem de Plaquetas/efeitos dos fármacos , Estudos Prospectivos , SegurançaRESUMO
Particle size distribution is a major determinant of particle clearance by the mononuclear phagocytic system and the potential for concomitant activation of resident macrophages. To test the safety of a second-generation perflubron-based emulsion (60% perfluorocarbon [PFC] wt/vol; Oxygent [Alliance Pharmaceutical Corp., San Diego, CA]) with a small mean particle size, two parallel, randomized, double-blinded, placebo-controlled studies were conducted in 48 healthy volunteers (n = 24 per study). The study described herein focuses on safety concerning immune function. The primary endpoint was defined prospectively as delayed hypersensitivity skin test responses with lymphocyte proliferative responses to mitogenic stimulation providing a secondary measure for changes in cell-mediated immunity. Subjects received either perflubron emulsion IV (1.2 g PFC/kg or 1.8 g PFC/kg) or saline (3 mL/kg) control. Perflubron emulsion had no effect on delayed hypersensitivity skin reactions, lymphocyte proliferative potential, circulating immunoglobulins, complement activation, or plasma levels of the inflammatory cytokines, tumor necrosis factor-alpha, interleukin-1 alpha, and interleukin-1 beta. Perflubron emulsion was generally well tolerated, although there was a dose-dependent increase in minor flu-like symptoms in the perflubron treatment groups at 24 h after dosing. Increased serum levels of interleukin-6 were observed in those subjects exhibiting febrile responses. The clinical safety profile of perflubron emulsion supports its continued investigation as a temporary oxygen carrier in surgical patients to reduce exposure to allogeneic blood transfusion.
Assuntos
Formação de Anticorpos/efeitos dos fármacos , Meios de Contraste/farmacologia , Fluorocarbonos/farmacologia , Imunidade Celular/efeitos dos fármacos , Adolescente , Adulto , Ativação do Complemento/efeitos dos fármacos , Meios de Contraste/administração & dosagem , Meios de Contraste/química , Meios de Contraste/farmacocinética , Relação Dose-Resposta a Droga , Método Duplo-Cego , Toxidermias/etiologia , Emulsões , Feminino , Fluorocarbonos/administração & dosagem , Fluorocarbonos/química , Fluorocarbonos/farmacocinética , Seguimentos , Humanos , Hidrocarbonetos Bromados , Hipersensibilidade Tardia/induzido quimicamente , Imunoglobulinas/efeitos dos fármacos , Injeções Intravenosas , Interleucina-1/sangue , Interleucina-6/sangue , Ativação Linfocitária/efeitos dos fármacos , Ativação de Macrófagos/efeitos dos fármacos , Ativação de Macrófagos/imunologia , Masculino , Pessoa de Meia-Idade , Tamanho da Partícula , Fagócitos/efeitos dos fármacos , Fagócitos/imunologia , Placebos , Estudos Prospectivos , Segurança , Fator de Necrose Tumoral alfa/efeitos dos fármacosRESUMO
PURPOSE: To describe the uses and determine the safety of a commercially available acellular dermal allograft in ophthalmic plastic and reconstructive surgery. The existing literature regarding current applications and results using acellular dermal allograft is reviewed. METHODS: The study design was a retrospective, noncomparative case series. Participants consisted of 63 consecutive patients undergoing ophthalmic plastic and reconstructive surgery using an acellular dermal matrix graft. The main intervention was placement of a dermal allograft. Outcome measures included the degree of clinical improvement and complications for each patient. RESULTS: We used AlloDerm (LifeCell Corporation, The Woodlands, TX, U.S.A.) as a posterior lamellar conjunctival spacer graft, a soft tissue interpositional graft, and an orbital implant wrapping material. Clinical improvement was noted in all cases. There were no complications attributable to the acellular dermal matrix material. CONCLUSIONS: We describe several novel ophthalmic plastic and reconstructive surgical applications using acellular dermal allograft tissue. This material may be used safely as a posterior lamellar conjunctival spacer graft, a soft tissue interpositional graft, and a wrapping material. Clinically, the allograft appears to be biocompatible, nontoxic, and nonallergenic in the orbit, eyelid, and midfacial tissues. Long-term data and studies comparing the efficacy of acellular dermal allograft with conventional materials are necessary.
Assuntos
Túnica Conjuntiva/cirurgia , Pálpebras/cirurgia , Órbita/cirurgia , Procedimentos de Cirurgia Plástica , Transplante de Pele , Cirurgia Plástica/métodos , Materiais Revestidos Biocompatíveis , Humanos , Implantes Orbitários , Estudos Retrospectivos , Segurança , Pele/citologia , Transplante HomólogoRESUMO
OBJECTIVE: To evaluate the safety and efficacy of orally administered perflubron for bowel recognition on MR imaging in a pediatric population. MATERIALS AND METHODS: A multicenter trial evaluated 39 pediatric subjects before and after ingestion of perflubron with T1-, proton-density, and T2-weighted sequences through the abdomen and/or pelvis. Post-contrast images were compared with pre-contrast images. Safety was evaluated through assessment of adverse events, clinical laboratory parameters, and vital signs. RESULTS: With regard to efficacy analysis, improvement in the percent of bowel darkened was observed for 85 % of the subjects on T1-weighted images and for 95 % of the subjects on proton-density and T2-weighted images. For images of the abdominal region, the percent of bowel darkened was improved for 90-92 % of the subjects across pulse sequences. Improvement rates for the images of the pelvic region ranged from 71 % to 100 %. For at least 75 % of the subjects, proton-density and T2-weighted images of the body and tail of the pancreas, left lobe of the liver, mesenteric fat, and pathological tissue were improved relative to predosing images. Twenty-three percent of the subjects experienced some adverse effects, most of which were minor and related to the digestive system. Clinical laboratory and vital sign evaluations revealed no trends associated with the administration of perflubron. CONCLUSION: Perflubron is a relatively safe and effective gastrointestinal MR contrast agent in the pediatric population.
Assuntos
Meios de Contraste , Fluorocarbonos , Intestinos/patologia , Imageamento por Ressonância Magnética , Abdome/patologia , Adolescente , Artefatos , Criança , Pré-Escolar , Meios de Contraste/efeitos adversos , Feminino , Fluorocarbonos/efeitos adversos , Humanos , Hidrocarbonetos Bromados , Lactente , Masculino , Estudos ProspectivosRESUMO
A perflubron emulsion is being developed as a contrast agent to enhance lymph nodes on computed tomography (CT) images. The emulsion is administered by percutaneous injection into the drainage field of the lymph nodes to be imaged. A series of preclinical studies was conducted to investigate the efficacy of the perflubron emulsion for enhancement of lymph nodes on CT images. The effects of dose (0.10 to 0.50 mL), application of massage, and route of administration were investigated in healthy New Zealand white rabbits. Results of these studies demonstrated that doses as low as 0.15 mL were efficacious for consistent enhancement of axillary lymph nodes on CT images after subcutaneous injections in the forepaw. Application of massage to the injection site decreased the time for maximum nodal enhancement from approximately 7 days to 2 days postinjection. A pilot study conducted in 18 healthy, male volunteers indicated dose-related enhancement of axillary lymph nodes on CT images following subcutaneous injections of the emulsion in the hand. Other than mild, transient injection-site discomfort, no clinically significant side effects were observed. These data demonstrate that the perflubron emulsion is safe and can enhance axillary lymph nodes on CT images following injections in the hand.
Assuntos
Meios de Contraste , Fluorocarbonos , Linfonodos/diagnóstico por imagem , Análise de Variância , Animais , Meios de Contraste/efeitos adversos , Relação Dose-Resposta a Droga , Vias de Administração de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Emulsões , Estudos de Avaliação como Assunto , Fluorocarbonos/efeitos adversos , Humanos , Hidrocarbonetos Bromados , Masculino , Massagem , Projetos Piloto , Coelhos , Tomografia Computadorizada por Raios XAssuntos
Morfina/farmacologia , Ureter/efeitos dos fármacos , Animais , Eletrofisiologia , Injeções Epidurais , CoelhosAssuntos
Eletromiografia , Músculo Liso/fisiologia , Ureter/fisiologia , Animais , Contração Muscular , CoelhosRESUMO
It has long been assumed that job satisfaction relates to employee turnover and quality of care. In this article the difficulties of measuring job satisfaction are discussed in light of results from a 6-month assessment by nurse employees in a university-affiliated acute care hospital. The authors found that job satisfaction scores were significantly predicted by respondents' job expectations and the importance they placed on various components of the work situation. The authors conclude that job satisfaction measurement is most valid and reliable when these two predictors are taken into account.
Assuntos
Satisfação no Emprego , Atitude , Humanos , Modelos Psicológicos , Enfermeiras e Enfermeiros/psicologia , Serviço Hospitalar de Enfermagem/organização & administração , Percepção , Reorganização de Recursos Humanos , Qualidade da Assistência à Saúde , Valores Sociais , Inquéritos e QuestionáriosAssuntos
Neoplasias Encefálicas/metabolismo , Sistema Nervoso Central/metabolismo , Mieloma Múltiplo/metabolismo , Proteínas do Mieloma/biossíntese , Plasmocitoma/metabolismo , Idoso , Neoplasias Encefálicas/imunologia , Feminino , Humanos , Imunoglobulina G/líquido cefalorraquidiano , Mieloma Múltiplo/imunologia , Plasmocitoma/imunologiaRESUMO
Antibody activity in IgG zones separated by thin-layer polyacrylamide gel isoelectric focusing (PAG IEF) was determined in 3 patients with subacute sclerosing panencephalitis (SSPE), 4 patients with multiple sclerosis (MS) and 4 subjects with psychosomatic disorders, using antigen immunofixation and autoradiography. Viral (measles herpes simplex type 1, mumps) and non-viral (purified bovine myelin, bovine myelin basic protein, bovine oligodendrocytes, MS and normal human brain extract) were used as antigens. All oligoclonal and some of the polyclonal CSF IgG zones in the patients with SSPE contained measles virus antibodies, as did some of the oligoclonal and polyclonal CSF IgG zones in 3 of the patients with MS. No antibodies were detectable in CSF or serum IgG zones against any of the non-viral antigens tested.
Assuntos
Antígenos Virais/análise , Imunoglobulina G/análise , Esclerose Múltipla/imunologia , Panencefalite Esclerosante Subaguda/imunologia , Adulto , Antígenos Virais/líquido cefalorraquidiano , Humanos , Imunoglobulina G/líquido cefalorraquidiano , Focalização Isoelétrica , Pessoa de Meia-Idade , Esclerose Múltipla/microbiologia , Panencefalite Esclerosante Subaguda/microbiologiaRESUMO
We report the extradural administration of low-dose morphine in 10 ml of 10% dextrose (2-3 mg) to 98 adult patients with various types of acute and chronic pain. Extradural morphine injections were given either via a Tuohy needle (single or repeat injection) or via an extradural catheter. Pain relief was evaluated by subjective scoring and by the subsequent need for systemic analgesics. In 56% of patients, pain relief was considered good or excellent, in 24% it was fair, and in 20%, poor. The best results were after surgery and trauma and in patients with advanced peripheral vascular disease. The analgesia of each dose of extradural morphine lasted for 8 h (mean range 4-36 h). There was no motor, sensory or sympathetic blockade and no respiratory or haemodynamic complications. Dizziness and vomiting occurred in two patients, and urinary retention for about 12 h in three.
Assuntos
Analgesia , Morfina/uso terapêutico , Dor/tratamento farmacológico , Adulto , Idoso , Anestesia Obstétrica , Esquema de Medicação , Espaço Epidural , Feminino , Humanos , Injeções , Masculino , Pessoa de Meia-Idade , Morfina/administração & dosagem , Dor Intratável/tratamento farmacológico , Dor Pós-Operatória/tratamento farmacológico , GravidezRESUMO
The endogenous central nervous tissue substance called MLC (morphine-like compound) is shown to bind to the opiate receptors of the mouse neuroblastoma X glioma hybrid cell line NG108-15. The interaction of MLC with these opiate receptors is noncooperative, as is the interaction of morphine, naloxone, and Leu-enkephalin with these receptors. A specific antibody to morphine will bind MLC but will not bind beta-endorphin, Leu-enkephalin, or Met-enkephalin. It would appear, therefore, that MLC can be considered to be a different type of endogenous ligand for the opiate receptor.
Assuntos
Entorpecentes/metabolismo , Receptores Opioides/metabolismo , Animais , Ligação Competitiva , Química Encefálica , Bovinos , Linhagem Celular , Membrana Celular/metabolismo , Encefalinas/metabolismo , Etorfina/metabolismo , Humanos , Técnicas In Vitro , Morfina/metabolismo , Naloxona/metabolismo , Entorpecentes/isolamento & purificação , RadioimunoensaioRESUMO
1. Renin-like activity was found in rat submaxillary glands.2. This activity was destroyed by boiling, was non-dialyzable and showed an optimum at approximately 50 degrees C.3. Renin-like activity in the submaxillary gland was not diminished 24 h after nephrectomy but was considerably reduced after ligature of the submaxillary duct.4. Renin-like activity in the submaxillary gland was reduced following food-deprivation, water-deprivation or hypovolemia.5. Renin-like activity in the rat submaxillary gland was increased after isoproterenol administration but not following pilocarpine.6. Renin-like activity in the rat submaxillary gland was increased considerably by administration of NaCl or KCl, as well as following adrenalectomy.7. Chlorothiazide and ouabain increased submaxillary renin-like activity but diazoxide did not affect this activity.